From: Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature
Logistic univariate regression analysis | Logistic multivariable regression analysis | |||
---|---|---|---|---|
Study characteristics | Odds ratio (95% CI)* | P-value | Odds ratio (95% CI)* | P-value |
Sample size | 0.99(0.99–1.00) | 0.11 | 1(0.99–1) | 0.58 |
Length of follow up (years) | 1.17(1.07–1.30) | 0.02 | 1.1(0.99–1.24) | 0.07 |
Date of publication (<2014 vs ≥2014) | 0.5(0.25–0.97) | 0.04 | 0.6(0.16–2.17) | 0.42 |
Journal type (high impact factor) | 3.5(1.78–7.5) | <0.001 | 0.4(0.1–1.55) | 0.19 |
Source of funding(industry funded vs non industry funded) | 1 .92(0.82–4.78) | 0.85 | 0.37 | |
Study area (pharmacological vs non pharmacological) | 0.26(0.13–0.51) | <0.001 | 0.25(0.09–0.66) | 0.007 |
Type of primary outcome | ||||
Binary | 1(reference) | – | 1(reference) | – |
Time to event | 3.05(1.41–6.80) | 0.05 | 2.22(0.72–7.12) | 0.17 |
Continuous | 0.91(0.38–2.17) | 0.83 | 0.98(0.26–3.7) | 0.98 |
Main effect of primary outcome (significant vs non significant) | 1.22(0.62–2.40) | 0.56 | 0.97(0.34–2.71) | 0.95 |
Newcastle-Ottawa Quality Assessment Score, n(%) (continuous) | ||||
0–3 4–6 7–8 | ref 1[0.13–6.70] 0.79[0.09–5.14] | ref 0.95 0.81 | ref 1.61(0.17–1.99) 1.75(0.12–2.3) | ref 0.70 0.66 |